लोड हो रहा है...
Targeting eIF4F translation initiation complex with SBI-756 sensitises B lymphoma cells to venetoclax
BACKGROUND: The BCL2 inhibitor venetoclax has shown efficacy in several hematologic malignancies, with the greatest response rates in indolent blood cancers such as chronic lymphocytic leukaemia. There is a lower response rate to venetoclax monotherapy in diffuse large B-cell lymphoma (DLBCL). METHO...
में बचाया:
| में प्रकाशित: | Br J Cancer |
|---|---|
| मुख्य लेखकों: | , , , , , , , , , , , , , |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
Nature Publishing Group UK
2020
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7960756/ https://ncbi.nlm.nih.gov/pubmed/33318657 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-01205-9 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|